Want to see SE:ERMA full AI Analyst Report?

Enorama Pharma AB (ERMA) Price & Analysis

0 Followers

ERMA Stock Chart & Stats

kr1.91

-kr0.30(-12.50%)

At close: Mar 06 4:00 PM EST

kr1.91

-kr0.30(-12.50%)

Day’s Range― - ―

52-Week Rangekr0.21 - kr3.00

Previous CloseN/A

Volume29.79K

Average Volume (3M)4.35K

Market Cap

kr78.32M

Enterprise Valuekr18.04

Total Cash (Recent Filing)kr17.76M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.54

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.91

Shares Outstanding74,588,684

10 Day Avg. Volume2,975

30 Day Avg. Volume4,348

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)-5.66

Price to Sales (P/S)48.45

P/FCF Ratio-2.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low DebtNear-zero debt limits interest and refinancing pressure, giving the company more flexibility to pursue product development or partnerships. However, this cushion is offset by negative equity and cash burn, so it does not remove future funding needs.

Prior Gross ProfitPositive gross profit in 2024 shows the product offering has at least once supported economics above direct costs. This provides evidence of potential operating viability, although materially negative current gross profit shows the benefit is not yet consistent.

Focused NRT PlatformA focused NRT platform can concentrate limited resources on a defined therapeutic need and support standardized product development. Commercialization through established partners could provide broader market access if regulatory and commercial milestones are achieved.

Bears Say

Very Small, Declining RevenueVery low and declining revenue indicates limited commercial scale and weak evidence of recurring demand. This constrains internal funding capacity, reduces operating leverage, and leaves the business dependent on successful commercialization or external capital.

Deep Losses And Weak MarginsSustained operating losses and deteriorating margins suggest the current cost structure is not supported by revenue. Unless pricing, production economics, or volume improves, the company may struggle to achieve self-funded operations over the next several quarters.

Cash Burn And Negative EquityPersistent cash burn combined with negative shareholders’ equity weakens financial resilience and limits flexibility to absorb setbacks. The company is likely to require external funding to sustain development, increasing dilution or financing-risk exposure.

ERMA FAQ

What was Enorama Pharma AB’s price range in the past 12 months?

Enorama Pharma AB lowest stock price was kr0.21 and its highest was kr3.00 in the past 12 months.

What is Enorama Pharma AB’s market cap?

Enorama Pharma AB’s market cap is kr78.32M.

When is Enorama Pharma AB’s upcoming earnings report date?

Enorama Pharma AB’s upcoming earnings report date is Nov 18, 2026 which is in 84 days.

How were Enorama Pharma AB’s earnings last quarter?

Enorama Pharma AB released its earnings results on Aug 19, 2026. The company reported -kr0.176 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Enorama Pharma AB overvalued?

According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enorama Pharma AB pay dividends?

Enorama Pharma AB does not currently pay dividends.

What is Enorama Pharma AB’s EPS estimate?

Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enorama Pharma AB have?

Enorama Pharma AB has 74,588,684 shares outstanding.

What happened to Enorama Pharma AB’s price movement after its last earnings report?

Enorama Pharma AB reported an EPS of -kr0.176 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.827%.

Which hedge fund is a major shareholder of Enorama Pharma AB?

Currently, no hedge funds are holding shares in SE:ERMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enorama Pharma AB

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.